Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: OGFOD3 (ImmuneEditome ID:79701)

1. Gene summary of enriched editing regions for OGFOD3

Gene summary

Gene information	Gene symbol	OGFOD3
	Gene ID	79701
	GeneSynonyms	C17orf101
	GeneCytomap	17q25.3
	GeneType	protein-coding
	GeneDescription	2-oxoglutarate and iron-dependent oxygenase domain-containing protein 3\|PKHD domain-containing transmembrane protein C17orf101
	GeneModificationdate	20230517
	UniprotID	Q6PK18;J3QLI8
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr17:82389486-82390056:-	ENST00000313056.8	ENSG00000181396.11	OGFOD3	UTR3	AluY,AluJb	chr17:82389486-82390056:-.alignment
chr17:82394037-82395283:-	ENST00000329197.8	ENSG00000181396.11	OGFOD3	exonic	AluJb,MER77,AluY	chr17:82394037-82395283:-.alignment

Top

2. Tumor-specific enriched editing regions for OGFOD3

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr17:82389486-82390056:-	KIRC	EER	5.3333e-03
ENSG00000181396.11,OGFOD3	KIRC	EAG	6.8302e-03
chr17:82389486-82390056:-	LUSC	EER	4.3792e-03
ENSG00000181396.11,OGFOD3	LUSC	EAG	4.5125e-03
ENSG00000181396.11,OGFOD3	UCEC	EAG	4.7020e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr17:82389486-82390056:-	LIHC	Path	EER	3.5872e-02	1.2823e-02	-0.1770
ENSG00000181396.11,OGFOD3	LIHC	Path	EAG	3.4258e-02	1.2258e-02	-0.1782
ENSG00000181396.11,OGFOD3	MESO	Path	EAG	3.5064e-02	1.0622e-02	0.3102
chr17:82389486-82390056:-	PAAD	Path	EER	1.7167e-02	7.8659e-03	0.2436
ENSG00000181396.11,OGFOD3	PAAD	Path	EAG	1.7167e-02	7.8659e-03	0.2436
ENSG00000181396.11,OGFOD3	UCEC	Cli	EAG	2.7482e-02	3.3352e-02	0.1491

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr17:82389486-82390056:-	HNSC	EER	2.1070e-02	7.8585e-03	2.2876e-02
ENSG00000181396.11,OGFOD3	HNSC	EAG	2.1070e-02	7.8585e-03	2.2876e-02

Top

3. Enriched editing regions and immune related genes for OGFOD3

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for OGFOD3

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

5. Enriched editing regions and immune infiltration for OGFOD3

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000181396.11,OGFOD3	ACC	EAG	Plasma_cells	1.8230e-02	0.3763
chr17:82389486-82390056:-	BLCA	EER	Macrophages_M1	1.2221e-04	0.2710
ENSG00000181396.11,OGFOD3	BLCA	EAG	Macrophages_M1	8.8701e-05	0.2749
chr17:82389486-82390056:-	BRCA	EER	Dendritic_cells_activated	1.9203e-05	0.1468
ENSG00000181396.11,OGFOD3	BRCA	EAG	Dendritic_cells_activated	1.7236e-05	0.1474
chr17:82389486-82390056:-	CESC	EER	Mast_cells_activated	2.9913e-03	0.2594
ENSG00000181396.11,OGFOD3	CESC	EAG	Mast_cells_activated	2.9759e-03	0.2595
ENSG00000181396.11,OGFOD3	CHOL	EAG	NK_cells_activated	8.1481e-03	0.5490
ENSG00000181396.11,OGFOD3	COAD	EAG	Dendritic_cells_activated	1.3411e-04	0.4697
chr17:82389486-82390056:-	ESCA	EER	Macrophages_M0	2.1963e-02	0.3267
chr17:82389486-82390056:-	GBM	EER	Macrophages_M0	4.6787e-05	-0.4011
ENSG00000181396.11,OGFOD3	GBM	EAG	Macrophages_M0	5.2506e-05	-0.3948
chr17:82389486-82390056:-	HNSC	EER	Mast_cells_activated	3.9325e-02	-0.1783
ENSG00000181396.11,OGFOD3	HNSC	EAG	Mast_cells_activated	3.8238e-02	-0.1786
chr17:82389486-82390056:-	KIRC	EER	Mast_cells_resting	1.4898e-02	-0.1462
ENSG00000181396.11,OGFOD3	KIRC	EAG	Mast_cells_resting	1.4681e-02	-0.1462
ENSG00000181396.11,OGFOD3	KIRP	EAG	Macrophages_M1	4.7931e-04	0.2665
chr17:82389486-82390056:-	LGG	EER	Macrophages_M0	4.1610e-02	-0.0929
ENSG00000181396.11,OGFOD3	LGG	EAG	Macrophages_M0	4.6099e-02	-0.0908
chr17:82389486-82390056:-	LIHC	EER	Macrophages_M1	5.4427e-03	0.1894
ENSG00000181396.11,OGFOD3	LIHC	EAG	Macrophages_M1	4.3364e-03	0.1938
chr17:82389486-82390056:-	LUAD	EER	T_cells_CD4_memory_activated	3.7893e-03	0.1587
ENSG00000181396.11,OGFOD3	LUAD	EAG	T_cells_CD4_memory_activated	3.7121e-03	0.1588
chr17:82389486-82390056:-	LUSC	EER	T_cells_gamma_delta	2.8085e-03	0.2097
ENSG00000181396.11,OGFOD3	LUSC	EAG	T_cells_gamma_delta	2.7541e-03	0.2096
ENSG00000181396.11,OGFOD3	MESO	EAG	Eosinophils	1.9000e-02	-0.2948
chr17:82389486-82390056:-	OV	EER	Macrophages_M0	1.7889e-02	-0.1919
ENSG00000181396.11,OGFOD3	OV	EAG	NK_cells_activated	2.0233e-02	0.1730
chr17:82389486-82390056:-	PAAD	EER	NK_cells_activated	3.9720e-02	-0.1880
ENSG00000181396.11,OGFOD3	PAAD	EAG	NK_cells_activated	3.9720e-02	-0.1880
chr17:82389486-82390056:-	PCPG	EER	Dendritic_cells_activated	3.3232e-02	0.1606
ENSG00000181396.11,OGFOD3	PCPG	EAG	Dendritic_cells_activated	3.3897e-02	0.1600
ENSG00000181396.11,OGFOD3	PRAD	EAG	T_cells_CD8	5.2948e-05	0.2120
chr17:82389486-82390056:-	SARC	EER	T_cells_CD8	1.1362e-03	0.2667
ENSG00000181396.11,OGFOD3	SARC	EAG	T_cells_CD8	1.4621e-03	0.2610
chr17:82389486-82390056:-	SKCM	EER	Macrophages_M2	1.1146e-02	-0.1587
ENSG00000181396.11,OGFOD3	SKCM	EAG	T_cells_CD4_memory_activated	1.0230e-02	0.1606
chr17:82389486-82390056:-	STAD	EER	B_cells_naive	4.8614e-02	0.1876
chr17:82394037-82395283:-	STAD	EER	T_cells_CD4_naive	2.3207e-06	0.6829
chr17:82389486-82390056:-	TGCT	EER	Macrophages_M2	9.0755e-06	-0.4163
ENSG00000181396.11,OGFOD3	TGCT	EAG	Macrophages_M2	9.0755e-06	-0.4163
chr17:82389486-82390056:-	THCA	EER	T_cells_regulatory_(Tregs)	5.0502e-03	0.1362
ENSG00000181396.11,OGFOD3	THCA	EAG	T_cells_regulatory_(Tregs)	4.6437e-03	0.1374
ENSG00000181396.11,OGFOD3	THYM	EAG	T_cells_follicular_helper	4.1698e-02	-0.2327
ENSG00000181396.11,OGFOD3	UCEC	EAG	Dendritic_cells_activated	3.2388e-03	0.2712

Top

6. Enriched editing regions and immune gene sets for OGFOD3

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr17:82389486-82390056:-	THCA	EER	9.9470e-03		1.5853e-02	0.1174
ENSG00000181396.11,OGFOD3	THCA	EAG	8.2147e-03		3.5358e-02	0.1024

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000181396.11,OGFOD3	ACC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	3.6247e-02	-0.3364
chr17:82389486-82390056:-	BLCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.0599e-05	0.3089
ENSG00000181396.11,OGFOD3	BLCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.0821e-05	0.3071
chr17:82389486-82390056:-	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.1637e-08	0.1951
ENSG00000181396.11,OGFOD3	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.0025e-08	0.1894
chr17:82389486-82390056:-	CESC	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EER	7.1329e-05	0.3424
ENSG00000181396.11,OGFOD3	CESC	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EAG	7.2314e-05	0.3421
ENSG00000181396.11,OGFOD3	CHOL	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	5.5531e-03	0.5706
ENSG00000181396.11,OGFOD3	COAD	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.1006e-05	-0.5304
ENSG00000181396.11,OGFOD3	ESCA	GSVA_HALLMARK_E2F_TARGETS	EAG	3.8347e-03	-0.3389
chr17:82389486-82390056:-	ESCA	GSVA_HALLMARK_G2M_CHECKPOINT	EER	1.2957e-02	-0.3526
chr17:82389486-82390056:-	GBM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.3127e-02	0.2510
ENSG00000181396.11,OGFOD3	GBM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	2.7107e-02	0.2222
ENSG00000181396.11,OGFOD3	HNSC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	3.6408e-02	0.1803
chr17:82389486-82390056:-	HNSC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	3.4460e-02	0.1829
ENSG00000181396.11,OGFOD3	KICH	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	1.2861e-02	-0.4999
ENSG00000181396.11,OGFOD3	KIRC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	4.2691e-03	-0.1709
chr17:82389486-82390056:-	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.4455e-03	0.1752
ENSG00000181396.11,OGFOD3	KIRP	GSVA_HALLMARK_APICAL_JUNCTION	EAG	5.9444e-03	-0.2114
chr17:82389486-82390056:-	LGG	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	5.8633e-09	0.2614
ENSG00000181396.11,OGFOD3	LGG	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	8.8915e-09	0.2579
ENSG00000181396.11,OGFOD3	LIHC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.8596e-05	0.2768
chr17:82389486-82390056:-	LIHC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	5.9838e-05	0.2708
chr17:82389486-82390056:-	LUAD	GSVA_HALLMARK_E2F_TARGETS	EER	4.1334e-04	0.1930
ENSG00000181396.11,OGFOD3	LUAD	GSVA_HALLMARK_E2F_TARGETS	EAG	4.4692e-04	0.1916
ENSG00000181396.11,OGFOD3	LUSC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	3.9159e-03	-0.2021
chr17:82389486-82390056:-	LUSC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	3.6127e-03	-0.2044
ENSG00000181396.11,OGFOD3	MESO	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	4.4732e-02	-0.2538
chr17:82389486-82390056:-	OV	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.2916e-05	0.3456
ENSG00000181396.11,OGFOD3	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	3.9905e-06	0.3360
chr17:82389486-82390056:-	PAAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	2.4322e-03	0.2743
ENSG00000181396.11,OGFOD3	PAAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	2.4322e-03	0.2743
ENSG00000181396.11,OGFOD3	PCPG	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	4.1074e-03	0.2153
chr17:82389486-82390056:-	PCPG	GSVA_HALLMARK_PROTEIN_SECRETION	EER	3.8633e-03	0.2167
ENSG00000181396.11,OGFOD3	PRAD	GSVA_HALLMARK_E2F_TARGETS	EAG	1.4114e-03	0.1681
chr17:82389486-82390056:-	SARC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.2488e-03	0.2646
ENSG00000181396.11,OGFOD3	SARC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.8438e-03	0.2556
ENSG00000181396.11,OGFOD3	SKCM	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.1435e-02	0.1582
chr17:82389486-82390056:-	SKCM	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.0728e-02	0.1595
chr17:82394037-82395283:-	STAD	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	8.0671e-03	0.4235
ENSG00000181396.11,OGFOD3	TGCT	GSVA_HALLMARK_MYOGENESIS	EAG	5.3590e-05	-0.3819
chr17:82389486-82390056:-	TGCT	GSVA_HALLMARK_MYOGENESIS	EER	5.3590e-05	-0.3819
ENSG00000181396.11,OGFOD3	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	7.0112e-07	0.2384
chr17:82389486-82390056:-	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	1.0299e-07	0.2555
ENSG00000181396.11,OGFOD3	THYM	GSVA_HALLMARK_APICAL_SURFACE	EAG	5.2772e-03	-0.3149
ENSG00000181396.11,OGFOD3	UCEC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	3.0667e-02	0.2008
ENSG00000181396.11,OGFOD3	UCS	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	3.3984e-03	-0.4369

Top

7. Enriched editing regions and drugs for OGFOD3

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000181396.11,OGFOD3	ACC	JNJ.26854165	EAG	4.8495e-02	0.3180
ENSG00000181396.11,OGFOD3	BLCA	CGP.082996	EAG	1.9116e-04	-0.2621
chr17:82389486-82390056:-	BLCA	CGP.082996	EER	8.6022e-05	-0.2768
chr17:82389486-82390056:-	BRCA	CGP.082996	EER	2.2798e-04	-0.1268
ENSG00000181396.11,OGFOD3	BRCA	CGP.082996	EAG	2.9974e-04	-0.1242
ENSG00000181396.11,OGFOD3	CESC	Gefitinib	EAG	1.5815e-04	-0.3266
chr17:82389486-82390056:-	CESC	Gefitinib	EER	1.5452e-04	-0.3271
ENSG00000181396.11,OGFOD3	CHOL	Doxorubicin	EAG	7.0484e-04	-0.6666
ENSG00000181396.11,OGFOD3	COAD	CCT007093	EAG	1.7848e-04	-0.4620
chr17:82389486-82390056:-	GBM	CEP.701	EER	3.0355e-03	0.2980
ENSG00000181396.11,OGFOD3	GBM	AKT.inhibitor.VIII	EAG	2.6900e-03	-0.2985
ENSG00000181396.11,OGFOD3	HNSC	BIRB.0796	EAG	2.1791e-02	0.1973
chr17:82389486-82390056:-	HNSC	BIRB.0796	EER	2.2099e-02	0.1976
chr17:82389486-82390056:-	KIRC	IPA.3	EER	5.7786e-07	-0.2950
ENSG00000181396.11,OGFOD3	KIRC	IPA.3	EAG	6.0989e-07	-0.2939
ENSG00000181396.11,OGFOD3	KIRP	AS601245	EAG	1.0073e-05	0.3334
chr17:82389486-82390056:-	LGG	Gemcitabine	EER	3.8415e-09	0.2645
ENSG00000181396.11,OGFOD3	LGG	Doxorubicin	EAG	4.0600e-09	0.2636
ENSG00000181396.11,OGFOD3	LIHC	IPA.3	EAG	2.2970e-03	0.2074
chr17:82389486-82390056:-	LIHC	BIRB.0796	EER	2.2502e-03	-0.2078
chr17:82389486-82390056:-	LUAD	CHIR.99021	EER	2.7975e-04	0.1988
ENSG00000181396.11,OGFOD3	LUAD	CHIR.99021	EAG	3.6870e-04	0.1946
chr17:82389486-82390056:-	LUSC	BMS.708163	EER	6.1327e-03	-0.1927
ENSG00000181396.11,OGFOD3	LUSC	AICAR	EAG	6.2963e-03	-0.1916
chr17:82389486-82390056:-	OV	Bosutinib	EER	2.6711e-03	0.2420
ENSG00000181396.11,OGFOD3	OV	Bexarotene	EAG	5.5453e-05	0.2958
chr17:82389486-82390056:-	PAAD	AMG.706	EER	3.0686e-03	0.2681
ENSG00000181396.11,OGFOD3	PAAD	AMG.706	EAG	3.0686e-03	0.2681
chr17:82389486-82390056:-	PCPG	JW.7.52.1	EER	3.0753e-03	0.2219
ENSG00000181396.11,OGFOD3	PCPG	JW.7.52.1	EAG	3.3403e-03	0.2200
ENSG00000181396.11,OGFOD3	PRAD	Bicalutamide	EAG	3.8384e-05	0.2158
ENSG00000181396.11,OGFOD3	SARC	Erlotinib	EAG	8.1122e-04	0.2742
chr17:82389486-82390056:-	SARC	Erlotinib	EER	5.5806e-04	0.2822
ENSG00000181396.11,OGFOD3	SKCM	CI.1040	EAG	5.4639e-03	-0.1735
chr17:82389486-82390056:-	SKCM	CI.1040	EER	8.1433e-03	-0.1654
chr17:82389486-82390056:-	STAD	CCT018159	EER	7.6560e-03	-0.2519
ENSG00000181396.11,OGFOD3	STAD	AMG.706	EAG	3.2965e-02	-0.1666
ENSG00000181396.11,OGFOD3	TGCT	Bryostatin.1	EAG	2.5648e-05	0.3966
chr17:82389486-82390056:-	TGCT	Bryostatin.1	EER	2.5648e-05	0.3966
chr17:82389486-82390056:-	THCA	Metformin	EER	2.1742e-08	0.2683
ENSG00000181396.11,OGFOD3	THCA	Metformin	EAG	7.0897e-08	0.2583
ENSG00000181396.11,OGFOD3	THYM	AICAR	EAG	1.1099e-02	-0.2880
ENSG00000181396.11,OGFOD3	UCEC	GSK.650394	EAG	1.5251e-02	0.2248
ENSG00000181396.11,OGFOD3	UVM	Erlotinib	EAG	1.8216e-02	0.4149

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType